Because of the lack of randomized controlled studies with masked outcomes, there is insufficient evidence to support or refute the efficacy of plasmapheresis in the treatment of myasthenic crisis (Level U) or MG prethymectomy (Level U).
CNS demyelinating disease
What is the efficacy of plasmapheresis in the treatment of CNS demyelinating disease?
Strong evidence
Plasmapheresis should not be offered for chronic progressive or secondary progressive multiple sclerosis (MS) (Level A).
Good evidence
Plasmapheresis should be considered for the adjunctive treatment of exacerbations in relapsing forms of MS (Level B).
Weak evidence
Plasmapheresis may be considered in the treatment of fulminant CNS demyelinating diseases that fail to respond to high-dose corticosteroid treatment (Level C).
Clinical context
No studies on the efficacy of plasmapheresis compared to other treatment options in MS are available. www.aan.com • (651) Copies of this summary and additional companion tools are available at www.aan.com or through AAN Member Services at (800) 879-1960.
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pediatric Autoimmune Neuropsychiatric disorders Associated With Streptoccocal Infection
What is the efficacy of plasmapheresis in the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (pANdAS)?
Insufficient evidence
There is insufficient evidence to support or refute the use of plasmapheresis in the treatment of acute obsessive-compulsive disorder (OCD) and tic symptoms in the setting of PANDAS (Level U).
Sydenham Chorea
What is the efficacy of plasmapheresis in the treatment of Sydenham chorea?
Insufficient evidence
There is insufficient evidence to support or refute the use of plasmapheresis in the treatment of Sydenham chorea (Level U).
